Antiestrogenic action of 3-hydroxytamoxifen in the human breast cancer cell line MCF-7

J Natl Cancer Inst. 1983 Jul;71(1):55-9.

Abstract

The antiestrogenic action of 3-hydroxytamoxifen [trans-1-(4-beta-dimethylaminoethoxyphenyl)-1-(3-hydroxyphenyl)-2 -phenylbut-1-ene] was characterized in vitro and compared with that of tamoxifen [trans-1-(4-beta-dimethylaminoethoxyphenyl)-1,2-diphenylbut-1-ene]. The relative binding affinities of 3-hydroxytamoxifen to estrogen receptor were 3.3% in cytosol of MCF-7 cells and 1.5% in human mammary carcinoma cytosol compared to values of 0.2 and 0.3% for tamoxifen (the affinity of 17 beta-estradiol considered to be 100%). The concentration of 3-hydroxytamoxifen necessary to suppress the 17 beta-estradiol-induced growth stimulation of MCF-7 cells was about tenfold lower than that for tamoxifen. The induction of progesterone receptor in MCF-7 cells by 17 beta-estradiol was inhibited by 3-hydroxytamoxifen. In the absence of 17 beta-estradiol, 3-hydroxytamoxifen gave rise to a moderate increase in the progesterone receptor levels, which demonstrates the partially estrogenic character of hydroxytamoxifen.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Binding, Competitive
  • Breast Neoplasms / metabolism*
  • Breast Neoplasms / pathology
  • Cell Division / drug effects
  • Cell Line
  • Cytosol / metabolism
  • Dose-Response Relationship, Drug
  • Estradiol / metabolism
  • Female
  • Humans
  • Receptors, Estrogen / metabolism*
  • Receptors, Progesterone / drug effects
  • Tamoxifen / analogs & derivatives*
  • Tamoxifen / pharmacology

Substances

  • Receptors, Estrogen
  • Receptors, Progesterone
  • Tamoxifen
  • droloxifene
  • afimoxifene
  • Estradiol